Lived Experiences of Women Diagnosed With HPV Infection

November 3, 2026 updated by: Ahmet Demirci, Bilecik Seyh Edebali Universitesi

Living Between Fear and Uncertainty: The Lived Experiences of Women Diagnosed With HPV Infection - A Phenomenological Study

This qualitative phenomenological study aims to explore the lived experiences of women diagnosed with human papillomavirus (HPV) infection. The study will examine women's emotional responses to the diagnosis, its perceived effects on daily life, sexual life and partner relationships, their experiences of disclosing the diagnosis, and their information and support needs. Eligible women diagnosed with HPV infection will participate in individual semi-structured interviews. The interview data will be analyzed thematically to identify common themes reflecting participants' experiences and perceptions.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study is designed as a qualitative phenomenological study to gain an in-depth understanding of the lived experiences of women diagnosed with HPV infection. Participants will be adult women with a confirmed HPV diagnosis who meet the eligibility criteria and provide written informed consent.

Data will be collected through individual face-to-face semi-structured interviews. The interview guide explores participants' experiences from the time of HPV diagnosis, emotional responses, perceived effects on daily and sexual life, partner relationships and disclosure experiences, concerns regarding future health, experiences with healthcare professionals, and perceived information and support needs. Interviews are expected to last approximately 30-45 minutes and will be audio-recorded with participants' permission.

Data collection will continue until data saturation is achieved, with approximately 15-20 participants anticipated. Interview recordings will be transcribed and analyzed thematically. Participant identities will be protected through coding, and personally identifying information will not be included in the analysis or reporting of the findings.

Study Type

Observational

Enrollment (Estimated)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey (Türkiye)
    • Bilecik
      • Bilecik, Bilecik, Turkey (Türkiye), 11230
        • Recruiting
        • Bilecik Training and Research Hospital
        • Sub-Investigator:
          • Aysun Acun, PhD
        • Contact:
        • Sub-Investigator:
          • Büşra Küçüktürkmen, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Adult women aged 18 years or older with a confirmed HPV infection who meet the eligibility criteria and voluntarily agree to participate in the study. Participants will be recruited among women evaluated at the study center and will undergo individual semi-structured interviews regarding their lived experiences following HPV diagnosis.

Description

Inclusion Criteria:

  • Confirmed diagnosis of HPV infection by HPV DNA testing
  • Ability to communicate verbally in Turkish
  • Willingness to participate in an individual semi-structured interview
  • Provision of written informed consent

Exclusion Criteria:

  • Inability to communicate adequately in Turkish
  • Cognitive or communication difficulties that would prevent participation in the interview
  • Refusal or withdrawal of informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: OTHER
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Women Diagnosed With HPV Infection

Adult women aged 18 years or older with a confirmed HPV infection who meet the eligibility criteria and provide written informed consent. Participants will take part in individual semi-structured interviews exploring their lived experiences following HPV diagnosis.
Other: Semi-Structured Interview

Participants will take part in an individual face-to-face semi-structured interview exploring their lived experiences following HPV diagnosis, including emotional responses, daily and sexual life, partner relationships, disclosure experiences, future health concerns, experiences with healthcare professionals, and information and support needs. Interviews are expected to last approximately 30-45 minutes and will be audio-recorded with participants' permission.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lived Experiences of Women Diagnosed With HPV Infection
Time Frame: At least 4 weeks after HPV diagnosis, following the initial acute adjustment period, during a single 30-45-minute semi-structured interview.

Participants' lived experiences following HPV diagnosis will be explored through individual semi-structured interviews. Interview transcripts will be analyzed thematically to identify themes related to emotional responses, daily and sexual life, partner relationships, disclosure experiences, future health concerns, interactions with healthcare professionals, and information and support needs.
At least 4 weeks after HPV diagnosis, following the initial acute adjustment period, during a single 30-45-minute semi-structured interview.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bilecik Seyh Edebali Universitesi

Investigators

  • Principal Investigator: Ahmet Demirci, Bilecik Seyh Edebali University Faculty of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

October 22, 2026

First Submitted That Met QC Criteria

November 3, 2026

First Posted (Actual)

November 5, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HPV-PHEN-2026-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be publicly shared due to the qualitative nature of the study and the potential risk of identifying participants from interview data. Data will be kept confidential and used only for the purposes of this study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe